A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer
Launched by HOFFMANN-LA ROCHE · Jun 11, 2007
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients, ≥ 70 years of age.
- • Cancer of the colon or rectum.
- • Metastatic disease diagnosed ≤ 6 months before enrollment.
- • ≥ 1 measurable metastatic lesion.
- Exclusion Criteria:
- • Adjuvant anti-vascular endothelial growth factor (VEGF) treatment.
- • Prior chemotherapeutic treatment for metastatic colorectal cancer.
- • Past or current history of other malignancies (with the exception of basal and squamous cell cancer of the skin, or in situ cancer of the cervix).
- • Clinically significant cardiovascular disease.
- • Current or recent daily use of aspirin (\> 325 mg/day) or other non-steroidal anti-inflammatory drug (NSAID), or full dose anticoagulants.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Roma, , Italy
Jaen, , Spain
Glasgow, , United Kingdom
Leicester, , United Kingdom
Manchester, , United Kingdom
Montreal, Quebec, Canada
Mexico City, , Mexico
Calgary, Alberta, Canada
Barcelona, , Spain
Madrid, , Spain
London, , United Kingdom
Budapest, , Hungary
Innsbruck, , Austria
Wien, , Austria
Linz, , Austria
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Zaragoza, , Spain
Leon, , Mexico
Toronto, Ontario, Canada
Sutton, , United Kingdom
Seoul, , Korea, Republic Of
Ljubljana, , Slovenia
Larissa, , Greece
Nottingham, , United Kingdom
Utrecht, , Netherlands
Firenze, , Italy
Warszawa, , Poland
Gyor, , Hungary
Incheon, , Korea, Republic Of
Eindhoven, , Netherlands
Salzburg, , Austria
Murcia, , Spain
Puebla, , Mexico
Apeldoorn, , Netherlands
Rhyl, , United Kingdom
Reggio Emilia, Emilia Romagna, Italy
Krakow, , Poland
Colchester, , United Kingdom
Piraeus, , Greece
Zalaegerszeg Pozva, , Hungary
Lecce, Puglia, Italy
Gyeonggi Do, , Korea, Republic Of
Las Palmas De Gran Canaria, Las Palmas, Spain
Leganes, Madrid, Spain
Bristol, , United Kingdom
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials